首页 正文

Long-term survival of patients who received atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma

{{output}}
Background: Immunotherapy combinations, such as atezolizumab plus bevacizumab (Atezo-Bev) or durvalumab plus tremelimumab, have been established as standard treatments for patients with advanced hepatocellular carcinoma (HCC). Du... ...